| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCL2L15 |
| Uniprot No | Q5TBC7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-163aa |
| 氨基酸序列 | MKSSQTFEEQTECIVNTLLMDFLSPTLQVASRNLCCVDEVDSGEPCSFDVAIIAGRLRMLGDQFNGELEASAKNVIAETIKGQTGAILQNTVESLSKTWCAQDSSLAYERAFLAVSVKLLEYMAHIAPEVVGQVAIPMTGMINGNQAIREFIQGQGGWENLES |
| 预测分子量 | 44.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCL2L15重组蛋白的参考文献示例(内容基于假设性研究，建议通过学术数据库核实具体文献)：
1. **《BCL2L15重组蛋白的表达及其促凋亡功能研究》**
- 作者：Zhang Y, Liu X, Wang J
- 摘要：本研究成功构建了BCL2L15重组蛋白表达系统，发现其在HeLa细胞中显著诱导caspase依赖性凋亡，提示BCL2L15可能通过线粒体途径调控细胞死亡。
2. **《Structural insights into BCL2L15 recombinant protein and its interaction with pro-survival BCL-2 family members》**
- 作者：Smith R, Brown K, Lee T
- 摘要：通过X射线晶体学解析BCL2L15重组蛋白结构，揭示其与BCL-XL和MCL-1的竞争性结合机制，为靶向凋亡通路的药物设计提供依据。
3. **《BCL2L15重组蛋白在结肠癌细胞中的抑癌作用及机制》**
- 作者：Chen L, Zhou H, Wei F
- 摘要：体外实验表明，重组BCL2L15蛋白通过抑制AKT/mTOR信号通路抑制结肠癌细胞增殖，并增强化疗药物敏感性。
4. **《Recombinant BCL2L15 protein induces autophagy via modulating Beclin-1 in neuronal cells》**
- 作者：Kim S, Park M, Jung Y
- 摘要：研究证实BCL2L15重组蛋白在神经元细胞中通过激活Beclin-1依赖的自噬途径，缓解氧化应激导致的细胞损伤。
建议通过PubMed或Google Scholar搜索上述关键词，获取真实文献及细节。
**Background of BCL2L15 Recombinant Protein**
BCL2L15. a member of the BCL-2 protein family, is implicated in the regulation of apoptosis—a critical process for maintaining cellular homeostasis. This family includes both pro- and anti-apoptotic proteins that govern mitochondrial outer membrane permeabilization (MOMP), a pivotal step in intrinsic apoptosis. BCL2L15 is classified as a pro-apoptotic protein, sharing structural homology with other BCL-2 family members, particularly through conserved BCL-2 homology (BH) domains. These domains mediate interactions with other family proteins to modulate cell survival or death.
The recombinant BCL2L15 protein is engineered using molecular cloning techniques, typically expressed in *E. coli* or mammalian systems to ensure proper folding and post-translational modifications. Purification methods, such as affinity chromatography, yield high-purity protein for functional studies. Its recombinant form enables researchers to explore its role in apoptotic pathways, including interactions with anti-apoptotic proteins (e.g., BCL-2. BCL-XL) or activation of pro-apoptotic effectors like BAX/BAK.
Current research on BCL2L15 remains limited compared to well-characterized family members, but emerging evidence suggests its involvement in tissue-specific apoptosis and potential links to diseases such as cancer. Dysregulation of apoptosis is a hallmark of malignancies, and BCL2L15's pro-apoptotic activity may position it as a tumor suppressor or a therapeutic target. Additionally, studies in model systems highlight its role in developmental processes and cellular stress responses.
Further investigation of BCL2L15 recombinant protein could clarify its mechanistic contributions to apoptosis, inform drug discovery efforts, and expand understanding of BCL-2 family dynamics in health and disease.
×
